Carl Erik Nord
Research Subjects
Carl Erik Nord has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Charlotta Edlund
Department of Microbiology, Pathology, and Immunology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden
5 shared publicationsC. Edlund
Department of Microbiology, Pathology and Immunology, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
4 shared publicationsSvante Sjöstedt
3 shared publicationsHong Fang
Department of Microbiology, Pathology, and Immunology, Karolinska Institute, Huddinge University Hospital, and Södertörns högskola (University College), Stockholm, Sweden
2 shared publicationsInger Adamsson
Department of Immunology, Microbiology, Pathology and Infectious Diseases, Huddinge University Hospital, Karolinska Institute, Stockholm, Sweden
2 shared publicationsMaria Hedberg
Department of Microbiology, Pathology, and Immunology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden
2 shared publications
Latest Publications
- 1 April 2003
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 9 (4) , 306-309
Will triclosan in toothpaste select for resistant oral streptococci?
- 1 April 2003
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 9 (4) , 306-309
Will triclosan in toothpaste select for resistant oral streptococci?
- Open Access
- 1 January 2003
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 9 (1) , 65-68
Dientamoeba fragilis—a protozoal infection which may cause severe bowel distress
- 1 January 2003
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 9 (1) , 65-68
Open AccessDientamoeba fragilis—a protozoal infection which may cause severe bowel distress
- Open Access
- 8 October 2002
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 50 (5) , 625-627
Probiotics in human infections
At the beginning of the last century, the Russian immunologist Elie Metchnikoff argued that life-long intake of yoghurt containing lactic acid-producing microorganisms could explain the differences in length of life between ethnic groups. The idea was that the bacteria in the fermented products competed with microorganisms that are injurious to health.1 Today it is known that the normal human microflora is important as a barrier against colonization by exogenous pathogenic microorganisms and potentially pathogenic bacteria already present in small numbers in the microflora.2 The normal microflora influence several biochemical, physiological and immunological features of the host, particularly the gastrointestinal flora, which consists of the most dense and diverse collection of bacteria.3 Disturbances in the normal microflora can be caused by several things, one being the administration of antimicrobial agents.4 Probiotic microorganisms are thought to counteract disturbances and thereby reduce the risk of colonization by pathogenic bacteria.5 Studies on strains of microorganisms used in probiotic dietary supplements have demonstrated that several strains produce antimicrobial substances such as organic acids, bacteriocins and peptides. In vitro and animal studies have further shown inhibitory effects of probiotic bacteria to be mediated by their interference with the adhesion of gastrointestinal pathogens or with toxins produced by the pathogenic microorganisms. Adjuvant-like effects on intestinal and systemic immunity have also been demonstrated for some strains.6 However, it is important to remember that even closely related strains have heterogeneous qualities.
- 8 October 2002
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 50 (5) , 625-627
Open AccessProbiotics in human infections
At the beginning of the last century, the Russian immunologist Elie Metchnikoff argued that life-long intake of yoghurt containing lactic acid-producing microorganisms could explain the differences in length of life between ethnic groups. The idea was that the bacteria in the fermented products competed with microorganisms that are injurious to health.1 Today it is known that the normal human microflora is important as a barrier against colonization by exogenous pathogenic microorganisms and potentially pathogenic bacteria already present in small numbers in the microflora.2 The normal microflora influence several biochemical, physiological and immunological features of the host, particularly the gastrointestinal flora, which consists of the most dense and diverse collection of bacteria.3 Disturbances in the normal microflora can be caused by several things, one being the administration of antimicrobial agents.4 Probiotic microorganisms are thought to counteract disturbances and thereby reduce the risk of colonization by pathogenic bacteria.5 Studies on strains of microorganisms used in probiotic dietary supplements have demonstrated that several strains produce antimicrobial substances such as organic acids, bacteriocins and peptides. In vitro and animal studies have further shown inhibitory effects of probiotic bacteria to be mediated by their interference with the adhesion of gastrointestinal pathogens or with toxins produced by the pathogenic microorganisms. Adjuvant-like effects on intestinal and systemic immunity have also been demonstrated for some strains.6 However, it is important to remember that even closely related strains have heterogeneous qualities.
- Open Access
- 1 September 2002
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 35 (s1) , S47-S53
Selection of Cefoxitin‐ResistantBacteroides thetaiotaomicronMutants and Mechanisms Involved in β‐Lactam Resistance
The β-lactam antibiotics are the most widely used of all the groups of antimicrobials, but β-lactam resistance is increasingly common among members o
- 1 September 2002
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 35 (s1) , S47-S53
Open AccessSelection of Cefoxitin‐ResistantBacteroides thetaiotaomicronMutants and Mechanisms Involved in β‐Lactam Resistance
The β-lactam antibiotics are the most widely used of all the groups of antimicrobials, but β-lactam resistance is increasingly common among members o
- 1 May 2002
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 19 (5) , 361-370
New findings in beta-lactam and metronidazole resistant Bacteroides fragilis group
- 1 May 2002
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 19 (5) , 361-370
New findings in beta-lactam and metronidazole resistant Bacteroides fragilis group
- 1 April 2002
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 8 (4) , 229-239
Ecological impact of the des-F(6)-quinolone, BMS-284756, on the normal intestinal microflora
- 1 April 2002
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 8 (4) , 229-239
Ecological impact of the des-F(6)-quinolone, BMS-284756, on the normal intestinal microflora
- Open Access
- 1 July 2001
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 7 (7) , 376-379
Effect of step-down therapy of ceftriaxone plus loracarbef versus parenteral therapy of ceftriaxone on the intestinal microflora in patients with community-acquired pneumonia
- 1 July 2001
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 7 (7) , 376-379
Open AccessEffect of step-down therapy of ceftriaxone plus loracarbef versus parenteral therapy of ceftriaxone on the intestinal microflora in patients with community-acquired pneumonia
- 1 January 2001
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 7, 37-41
The evaluation and prediction of the ecologic impact of antibiotics in human phase I and II trials.
- 1 January 2001
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 7, 37-41
The evaluation and prediction of the ecologic impact of antibiotics in human phase I and II trials.
- Open Access
- 1 October 2000
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 46 (4) , 603-612
Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil
Thirty healthy volunteers in three groups participated in a study of the effect on the intestinal microflora of oral supplementation with Bifidobacterium longum, Lactobacillus acidophilus and oligofructose, an indigestible oligosaccharide, during oral administration of cefpodoxime proxetil bd for 7 days. Those in group A also received an oral supplement with c.1011 cfu of B. longum BB 536 and L. acidophilus NCFB 1748 and 15 g oligofructose daily, those in group B received a supplement with oligofructose only and those in group C received placebo, for 21 days. In all three groups there was a marked decrease in aerobic microorganisms, involving mainly a rapid and almost complete disappearance of Escherichia coli (P < 0.05) during antimicrobial administration and, thereafter, an overgrowth of enterococci (P < 0.05). The number of intestinal yeasts also increased significantly (P < 0.05) in groups A and B over the same period. There was a dramatic decrease in anaerobic microorganisms on day 4 of administration, mainly caused by loss of bifidobacteria (P < 0.05) in all groups. The number of lactobacilli also decreased but was significantly higher in group A than in group C at the end of cefpodoxime proxetil administration. Clostridium difficile was found in only one person from group A, but six persons each in groups B and C. Of the bifidobacterial strains isolated from the faecal samples in group A, one was similar to the strain of B. longum administered, but most volunteers were colonized by several different strains of B. longum during the investigation period. The administered strain of L. acidophilus was recovered from six patients in group A.
- 1 October 2000
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 46 (4) , 603-612
Open AccessEffect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil
Thirty healthy volunteers in three groups participated in a study of the effect on the intestinal microflora of oral supplementation with Bifidobacterium longum, Lactobacillus acidophilus and oligofructose, an indigestible oligosaccharide, during oral administration of cefpodoxime proxetil bd for 7 days. Those in group A also received an oral supplement with c.1011 cfu of B. longum BB 536 and L. acidophilus NCFB 1748 and 15 g oligofructose daily, those in group B received a supplement with oligofructose only and those in group C received placebo, for 21 days. In all three groups there was a marked decrease in aerobic microorganisms, involving mainly a rapid and almost complete disappearance of Escherichia coli (P < 0.05) during antimicrobial administration and, thereafter, an overgrowth of enterococci (P < 0.05). The number of intestinal yeasts also increased significantly (P < 0.05) in groups A and B over the same period. There was a dramatic decrease in anaerobic microorganisms on day 4 of administration, mainly caused by loss of bifidobacteria (P < 0.05) in all groups. The number of lactobacilli also decreased but was significantly higher in group A than in group C at the end of cefpodoxime proxetil administration. Clostridium difficile was found in only one person from group A, but six persons each in groups B and C. Of the bifidobacterial strains isolated from the faecal samples in group A, one was similar to the strain of B. longum administered, but most volunteers were colonized by several different strains of B. longum during the investigation period. The administered strain of L. acidophilus was recovered from six patients in group A.
- 1 October 2000
- Published by Springer Nature in Infection
- Vol. 28 (5) , 272-277
Ecological Disturbances in Intestinal Microflora Caused by Clinafloxacin, an Extended-Spectrum Quinolone
Background: The quinolones developed over the past few years have enhanced in vitro activity and a broader spectrum of antimicrobial activity compared to many other antimicrobial agents including the older quinolones. The present study focuses on the effect of clinafloxacin, a member of the new broadspectrum quinolone class of antibiotics, on the normal intestinal microflora. Subjects and Methods: A total of 12 healthy volunteers received clinafloxacin orally, 200 mg twice daily for 7 days. Fecal specimens were collected at defined intervals before, during and after the administration in order to study the effect of clinafloxacin on the intestinal microflora and to correlate this effect with fecal clinafloxacin concentrations. Intestinal microorganisms isolated before, during and 2 weeks after clinafloxacin administration were tested for their suseptibility to clinafloxacin. Results: Oral administration of clinafloxacin resulted in high drug levels in feces (mean value 176.2 mg/kg on day 7) and pronounced ecological disturbances. The aerobic microflora was eradicated in 11 of the 12 subjects and the anaerobic microflora was strongly suppressed during administration. There was a significant emergence of clinafloxacin-resistant Bacteroides spp. strains (MIC ≥ 4 mg/ml) during administration. The elevated MIC values still remained 2 weeks after discontinuation of the antibiotic (p < 0.001). Conclusion: The emergence of clinafloxacin-resistant Bacteroides spp. demonstrates the necessity of restricting prescription for particular indications in order to preserve the efficacy of the highly active broad-spectrum quinolones.
- 1 October 2000
- Published by Springer Nature in Infection
- Vol. 28 (5) , 272-277
Ecological Disturbances in Intestinal Microflora Caused by Clinafloxacin, an Extended-Spectrum Quinolone
Background: The quinolones developed over the past few years have enhanced in vitro activity and a broader spectrum of antimicrobial activity compared to many other antimicrobial agents including the older quinolones. The present study focuses on the effect of clinafloxacin, a member of the new broadspectrum quinolone class of antibiotics, on the normal intestinal microflora. Subjects and Methods: A total of 12 healthy volunteers received clinafloxacin orally, 200 mg twice daily for 7 days. Fecal specimens were collected at defined intervals before, during and after the administration in order to study the effect of clinafloxacin on the intestinal microflora and to correlate this effect with fecal clinafloxacin concentrations. Intestinal microorganisms isolated before, during and 2 weeks after clinafloxacin administration were tested for their suseptibility to clinafloxacin. Results: Oral administration of clinafloxacin resulted in high drug levels in feces (mean value 176.2 mg/kg on day 7) and pronounced ecological disturbances. The aerobic microflora was eradicated in 11 of the 12 subjects and the anaerobic microflora was strongly suppressed during administration. There was a significant emergence of clinafloxacin-resistant Bacteroides spp. strains (MIC ≥ 4 mg/ml) during administration. The elevated MIC values still remained 2 weeks after discontinuation of the antibiotic (p < 0.001). Conclusion: The emergence of clinafloxacin-resistant Bacteroides spp. demonstrates the necessity of restricting prescription for particular indications in order to preserve the efficacy of the highly active broad-spectrum quinolones.